Evidence Library

Filter by drug, type, year, and open access.

Drug

Type

Year ≥

Sort

Open access

Active filters:Type: GUIDELINE ×Clear filters

Showing 51–100 of 112 results

ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: oxazepamDOI
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)• Drug: chlordiazepoxideDOI
ASAM guideline on benzodiazepine tapering and prescribing — Journal of Addiction Medicine (2020)• Drug: chlordiazepoxideDOI
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: buprenorphineDOI PMID
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: buprenorphine-naloxoneDOI PMID
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: methadoneDOI PMID
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)• Drug: naltrexone-extended-releaseDOI PMID
ASAM guideline on benzodiazepines — Journal of Addiction Medicine (2020)• Drug: lorazepamDOI
Bipolar disorder: assessment and management (NICE guideline CG185) — National Institute for Health and Care Excellence (2020)• Drug: valproate-divalproexOpen access
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: methylphenidateDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: dexmethylphenidateDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: amphetamine-dextroamphetamineDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: lisdexamfetamineDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: atomoxetineDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: guanfacine-erDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: clonidineDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: clonidine-erDOI
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: guanfacineDOI
Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders — Neurology (PMC) (2019)• Drug: pimozideOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents — Pediatrics (2019)• Drug: viloxazineDOI
AGNP Consensus Guidelines for TDM in Psychiatry — Pharmacopsychiatry (2018)• Drug: clozapineOpen access
CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. — Bipolar Disorders (2018)• Drug: valproateOpen accessDOI PMID PMCID
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: methylphenidateOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: dexmethylphenidateOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: amphetamine-dextroamphetamineOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: lisdexamfetamineOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: atomoxetineOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: guanfacine-erOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: clonidineOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: clonidine-erOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: guanfacineOpen access
Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE Guideline NG87 (2018)• Drug: viloxazineOpen access
The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder — American Journal of Psychiatry (2018)• Drug: naltrexoneDOI PMID
The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder — American Journal of Psychiatry (2018)• Drug: acamprosateDOI PMID
The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder — American Journal of Psychiatry (2018)• Drug: disulfiramDOI PMID
AGNP Consensus Guidelines for TDM in Psychiatry — Pharmacopsychiatry (2018)• Drug: amoxapineOpen access
AGNP Consensus Guidelines for TDM in Psychiatry — Pharmacopsychiatry (2018)• Drug: nefazodoneOpen access
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus — CNS Spectrums (2018)• Drug: pimavanserinPMID
AGNP Consensus Guidelines for TDM in Psychiatry — Pharmacopsychiatry (2018)• Drug: trimipramineOpen access
AGNP Consensus Guidelines for TDM in Psychiatry — Pharmacopsychiatry (2018)• Drug: valproate-divalproexOpen access
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: eszopicloneOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: zolpidemOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: ramelteonOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: suvorexantOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: lemborexantOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: daridorexantOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: zaleplonOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: estazolamOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: flurazepamOpen accessDOI PMID PMCID
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)• Drug: quazepamOpen accessDOI PMID PMCID